Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy

References

• WangZYChenZAcute promyelocytic leukemia: from highly fatal to highly curableBlood200811152505251518299451
   PubMed Web of Science ®Google Scholar
• SanzMAGrimwadeDTallmanMSManagement of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetBlood200911391875189118812465
   PubMed Web of Science ®Google Scholar
• SanzMAMontesinosPRayónCRisk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcomeBlood2010115255137514620393132
   PubMed Web of Science ®Google Scholar
• Lo-CocoFAvvisatiGVignettiMItalian GIMEMA Cooperative GroupFront-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA GroupBlood2010116173171317920644121
   PubMed Web of Science ®Google Scholar
• ShenZXChenGQNiJHUse of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patientsBlood1997899335433609129042
   PubMed Web of Science ®Google Scholar
• SoignetSLFrankelSRDouerDUnited States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemiaJ Clin Oncol200119183852386011559723
   PubMed Web of Science ®Google Scholar
• BrecciaMLo-CocoFArsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent diseaseExpert Opin Pharmacother20121371031104322468778
   PubMed Web of Science ®Google Scholar
• IlandHJBradstockKSuppleSGAustralasian Leukaemia and Lymphoma GroupAll-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)Blood2012120815701580 quiz 175222715121
   PubMed Web of Science ®Google Scholar
• PowellBLMoserBStockWArsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710Blood2010116193751375720705755
   PubMed Web of Science ®Google Scholar
• RavandiFEsteyEJonesDEffective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicinJ Clin Oncol200927450451019075265
   PubMed Web of Science ®Google Scholar
• ShenZXShiZZFangJAll-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemiaProc Natl Acad Sci U S A2004101155328533515044693
   PubMed Web of Science ®Google Scholar
• GoreSDGojoISekeresMASingle cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemiaJ Clin Oncol20102861047105320085935
   PubMed Web of Science ®Google Scholar
• TallmanMSAndersenJWSchifferCAAll-trans-retinoic acid in acute promyelocytic leukemiaN Engl J Med199733715102110289321529
   PubMed Web of Science ®Google Scholar
• FenauxPChastangCChevretSA randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL GroupBlood19999441192120010438706
   PubMed Web of Science ®Google Scholar
• TallmanMSAndersenJWSchifferCAAll-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolBlood2002100134298430212393590
   PubMed Web of Science ®Google Scholar
• AdèsLGuerciARaffouxEEuropean APL GroupVery long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experienceBlood201011591690169620018913
   PubMed Web of Science ®Google Scholar
• AvvisatiGLo-CocoFPaoloniFPGIMEMA, AIEOP, and EORTC Cooperative GroupsAIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenanceBlood2011117184716472521385856
   PubMed Web of Science ®Google Scholar
• MuchtarEVidalLRamRGafter-GviliAShpilbergORaananiPThe role of maintenance therapy in acute promyelocytic leukemia in the first complete remissionCochrane Database Syst Rev20133CD009594
   Google Scholar
• LouYQianWMengHHigh efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemiaLeuk Res2013371374223017225
   PubMedGoogle Scholar
• ChiangYHChangYFHsiehRKUpfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtypeAsia Pac J Clin Oncol20128433033622897350
   PubMedGoogle Scholar
• US Department of Health and Human ServicesNational Institutes of HealthNational Cancer InstituteCommon Terminology Criteria for Adverse Events (CTCAE), Version 4.0 Published May 28, 2009 (v4.03: June 14, 2010 Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf)Accessed April 13, 2017
   Google Scholar
• SagieALarsonMGGoldbergRJBengtsonJRLevyDAn improved method for adjusting the QT interval for heart rate (the Framingham Heart Study)Am J Cardiol19927077978011519533
   PubMed Web of Science ®Google Scholar
• AuWYKumanaCRLeeHKOral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up studyBlood2011118256535654321998212
   PubMed Web of Science ®Google Scholar
• ZhuJKokenMHQuignonFArsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemiaProc Natl Acad Sci U S A1997948397839839108090
   PubMed Web of Science ®Google Scholar
• ShaoWFanelliMFerraraFFArsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cellsJ Natl Cancer Inst19989021241339450572
   PubMed Web of Science ®Google Scholar
• RobozGJDiasSLamGArsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesisBlood20009641525153010942401
   PubMed Web of Science ®Google Scholar
• ChenSJZhouGBZhangXWMaoJHde ThéHChenZFrom an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaBlood2011117246425643721422471
   PubMed Web of Science ®Google Scholar
• Lallemand-BreitenbachVGuilleminMCJaninARetinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemiaJ Exp Med199918971043105210190895
   PubMed Web of Science ®Google Scholar
• de ThéHChenZAcute promyelocytic leukaemia: novel insights into the mechanisms of cureNat Rev Cancer2010101177578320966922
   PubMed Web of Science ®Google Scholar
• MaYLiuLJinJLouYAll-trans retinoic acid plus arsenic trioxide versus all-trans retinoic acid plus chemotherapy for newly diagnosed acute promyelocytic leukemia: a meta-analysisPLoS One2016117e015876027391027
   PubMed Web of Science ®Google Scholar
• PlatzbeckerUAvvisatiGCicconiLImproved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trialJ Clin Oncol201735660561227400939
   PubMed Web of Science ®Google Scholar
• FirkinFCarcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern?Leuk Lymphoma201455597797824144311
   PubMed Web of Science ®Google Scholar
• RezukeWNAndersonCPastuszakWTConwaySRFirsheinSIArsenic intoxication presenting as a myelodysplastic syndrome: a case reportAm J Hematol19913642912932012077
   PubMedGoogle Scholar
• HuJLiuYFWuCFLong-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemiaProc Natl Acad Sci U S A200910693342334719225113
   PubMed Web of Science ®Google Scholar
• GhavamzadehAAlimoghaddamKRostamiSPhase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemiaJ Clin Oncol201129202753275721646615
   PubMed Web of Science ®Google Scholar
• MathewsVGeorgeBLakshmiKMSingle-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicityBlood200610772627263216352810
   PubMed Web of Science ®Google Scholar
• Lo-CocoFAvvisatiGVignettiMfor Gruppo Italiano Malattie Ematologiche dell’Adulto, the German–Austrian Acute Myeloid Leukemia Study Group, and Study Alliance LeukemiaRetinoic acid and arsenic trioxide for acute promyelocytic leukemiaN Engl J Med2013369211112123841729
   PubMed Web of Science ®Google Scholar
• BurnettAKRussellNHHillsRKUK National Cancer Research Institute Acute Myeloid Leukaemia Working GroupArsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trialLancet Oncol201516131295130526384238
   PubMed Web of Science ®Google Scholar
• IlandHJCollinsMBradstockKAustralasian Leukaemia and Lymphoma GroupUse of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trialLancet Haematol201529e357e36626685769
   PubMed Web of Science ®Google Scholar
• CoutreSEOthusMPowellBArsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapyBr J Haematol2014165449750324528179
   PubMed Web of Science ®Google Scholar